DrugPatentWatch Database Preview
ELIQUIS Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Eliquis, and what generic alternatives are available?
Eliquis is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and thirty-nine patent family members in forty countries.
The generic ingredient in ELIQUIS is apixaban. There are twenty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apixaban profile page.
Summary for ELIQUIS
| International Patents: | 139 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 91 |
| Clinical Trials: | 40 |
| Patent Applications: | 833 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ELIQUIS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ELIQUIS |
| DailyMed Link: | ELIQUIS at DailyMed |
Generic Entry Opportunity Date for ELIQUIS
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ELIQUIS
| Drug Class | Factor Xa Inhibitor |
| Mechanism of Action | Factor Xa Inhibitors |
Synonyms for ELIQUIS
| 1-(4-Methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide |
| 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidyl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-car |
| 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide?BMS-562247; BMS-562247-01 |
| 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)- |
| 1H-Pyrazolo[3,4-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]- |
| 2p16 |
| 3Z9Y7UWC1J |
| 4,5,6,7-TETRAHYDRO-1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXO-1-PIPERIDINYL)PHENYL]-1H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXAMIDE |
| 503612-47-3 |
| 612A473 |
| AB0007933 |
| AB01565766_02 |
| AB1008435 |
| ABP000333 |
| AC-26301 |
| AJ-59962 |
| AK161862 |
| AKOS005146204 |
| AN-429 |
| AOB87769 |
| Apixaban |
| Apixaban - Adooq Bioscience |
| Apixaban (BMS 562247-01) |
| Apixaban (JAN/USAN/INN) |
| Apixaban [USAN] |
| Apixaban BMS-562247-01 |
| Apixaban,BMS-562247-01 |
| Apixaban;503612-47-3 |
| Apixaban(BMS-562247-01) |
| Apixaban/BMS562247-01/Apixaban |
| apixabanum |
| Apixabin |
| AX8161411 |
| BC654125 |
| BCP9000310 |
| BCPP000396 |
| BDBM19023 |
| BMS 562247 |
| BMS 562247-01 |
| BMS-562247 |
| BMS-562247-01 |
| BMS-562247-01, Apixaban |
| BMS562247-01 |
| CA0186 |
| CCG-229675 |
| CHEBI:72296 |
| CHEMBL231779 |
| CS-0401 |
| D03213 |
| D0I5HF |
| DB06605 |
| DTXSID80436500 |
| Eliquis (TN) |
| EX-A048 |
| FT-0686944 |
| GG2 |
| GTPL6390 |
| HE069298 |
| HE346199 |
| HMS3655O07 |
| HY-50667 |
| I14-11577 |
| J-200194 |
| KB-47429 |
| KS-0000075V |
| ME-0152 |
| MFCD11977295 |
| MLS006010026 |
| MolPort-006-170-153 |
| NCGC00346555-01 |
| PB10976 |
| PYR431 |
| Q-4456 |
| QC-8191 |
| QNZCBYKSOIHPEH-UHFFFAOYSA-N |
| ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide |
| RP18047 |
| s1593 |
| SC-49755 |
| SCHEMBL118023 |
| SMR004676529 |
| ST24045978 |
| UNII-3Z9Y7UWC1J |
| X1060 |
| ZINC11677837 |
US Patents and Regulatory Information for ELIQUIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-002 | Dec 28, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for ELIQUIS
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | ➤ Sign Up |
Non-Orange Book US Patents for ELIQUIS
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,338,963 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ➤ Sign Up |
| 6,673,810 | Imidazo-heterobicycles as factor Xa inhibitors | ➤ Sign Up |
| 7,371,761 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for ELIQUIS
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Taiwan | 200918052 | ➤ Sign Up |
| European Patent Office | 3017811 | ➤ Sign Up |
| New Zealand | 601738 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for ELIQUIS
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 3 | Finland | ➤ Sign Up | |
| 0110017 00045 | Estonia | ➤ Sign Up | PRODUCT NAME: ELIQUIS - APIKSABAAN; REG NO/DATE: C(2011)3595 18.05.2011 |
| 90029-7 | Sweden | ➤ Sign Up | PRODUCT NAME: APIXABAN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/11/691/001-005 20110518 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
